FAETH THERAPEUTICS INC

FAETH Therapeutics insider buys 25,000 options—showing confidence in a rising oncology platform amid volatile early‑stage performance.

FAETH THERAPEUTICS gains momentum as Khosla Ventures’ large stake and insider buying signal long‑term confidence in its oncology pipeline.

Insider buying surge at Faeth Therapeutics signals strong confidence in its CAR‑T pipeline—CFO’s trust purchases hint at upside potential for value investors.